Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer
Publication date
2020-01-02
Authors
Yao, Ye
Xu, Xiaoya
Yang, Lifeng
Zhu, Ji
Wan, Juefeng
Shen, Lijun
Xia, Fan
Fu, Guoxiang
Deng, Yun
Pan, Mengxue
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Accumulating evidence indicates that patient-derived organoids (PDOs) can predict drug responses in the clinic, but the ability of PDOs to predict responses to chemoradiation in cancer patients remains an open question. Here we generate a living organoid biobank from patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiation (NACR) enrolled in a phase III clinical trial. Our co-clinical trial data confirm that rectal cancer organoids (RCOs) closely recapitulate the pathophysiology and genetic changes of corresponding tumors. Chemoradiation responses in patients are highly matched to RCO responses, with 84.43% accuracy, 78.01% sensitivity, and 91.97% specificity. These data imply that PDOs predict LARC patient responses in the clinic and may represent a companion diagnostic tool in rectal cancer treatment.
Keywords
chemoradiation, clinical response, organoids, predict, rectal cancer, Taverne, Molecular Medicine, Genetics, Cell Biology
Citation
Yao, Y, Xu, X, Yang, L, Zhu, J, Wan, J, Shen, L, Xia, F, Fu, G, Deng, Y, Pan, M, Guo, Q, Gao, X, Li, Y, Rao, X, Zhou, Y, Liang, L, Wang, Y, Zhang, J, Zhang, H, Li, G, Zhang, L, Peng, J, Cai, S, Hu, C, Gao, J, Clevers, H, Zhang, Z & Hua, G 2020, 'Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer', Cell Stem Cell, vol. 26, no. 1, pp. 17-26.e6. https://doi.org/10.1016/j.stem.2019.10.010